The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence

The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence

Despite improvements for management of type 1 diabetes (T1D), patients have difficulty achieving glycated hemoglobin (A1c) levels recommended by the Diabetes Control and Complications Trial (DCCT). Two multicenter randomized trials were conducted to evaluate benefit of using a continuous glucose mon...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiovascular translational research 2012-08, Vol.5 (4), p.380-387
Hauptverfasser: Ruedy, Katrina J., Tamborlane, William V.
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adult
Biomarkers - blood
Biomedical Engineering and Bioengineering
Biomedicine
Blood Glucose - drug effects
Blood Glucose - metabolism
Blood Glucose Self-Monitoring - instrumentation
Cardiology
Child
Diabetes Mellitus, Type 1 - blood
Diabetes Mellitus, Type 1 - diagnosis
Diabetes Mellitus, Type 1 - drug therapy
Equipment Design
Evidence-Based Medicine
Glycated Hemoglobin A - metabolism
Human Genetics
Humans
Hypoglycemia - blood
Hypoglycemia - chemically induced
Hypoglycemia - prevention & control
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Medicine
Medicine & Public Health
Multicenter Studies as Topic
Patient Satisfaction
Predictive Value of Tests
Randomized Controlled Trials as Topic
Time Factors
Treatment Outcome
United States
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Despite improvements for management of type 1 diabetes (T1D), patients have difficulty achieving glycated hemoglobin (A1c) levels recommended by the Diabetes Control and Complications Trial (DCCT). Two multicenter randomized trials were conducted to evaluate benefit of using a continuous glucose monitor (CGM) with standard glucose monitoring for T1D management. The primary study evaluated benefits of CGM in 322 patients with A1c >7.0 %. The secondary study evaluated 129 patients with A1c 25 years, but not those
ISSN:1937-5387
1937-5395
DOI:10.1007/s12265-012-9364-9